Zevra Therapeutics (ZVRA) Accounts Payables (2014 - 2026)

Zevra Therapeutics has reported Accounts Payables for 13 years, with the latest figure at $11.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 34.41% year-over-year to $11.7 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (down 34.41% YoY), and the FY2025 full-year result was $11.6 million, down 54.44% from the prior year.
• Accounts Payables for Q1 2026 stood at $11.7 million, up from $11.6 million in the prior quarter.
• The five-year high for Accounts Payables was $25.5 million in Q4 2024, with the low at $393000.0 in Q1 2023.
• Historically, Accounts Payables has averaged $12.8 million across 5 years, with a median of $12.4 million in 2023.
• Annual changes were most pronounced in 2023 — Accounts Payables sank 84.78% — and 2024, when it soared 5697.71%.
• Zevra Therapeutics' Accounts Payables stood at $6.2 million in 2022, then jumped by 126.73% to $14.0 million in 2023, then jumped by 82.0% to $25.5 million in 2024, then slumped by 54.44% to $11.6 million in 2025, then climbed by 0.78% to $11.7 million in 2026.
• The last three Accounts Payables figures came in at $11.7 million (Q1 2026), $11.6 million (Q4 2025), and $11.1 million (Q3 2025), per Business Quant data.